InvestorsHub Logo
Followers 655
Posts 19047
Boards Moderated 3
Alias Born 07/03/2011

Re: None

Thursday, 12/28/2023 3:34:52 PM

Thursday, December 28, 2023 3:34:52 PM

Post# of 347
C4 Therapeutics, or C4T, is a clinical-stage biopharmaceutical company focused on developing a new generation of medicines that harness targeted protein degradation (TPD). To achieve this objective, C4T utilizes its proprietary TORPEDO platform to design, analyze and predict degrader performance. Earlier this month, it signed a collaboration deal with Merck to discover and develop degrader-antibody conjugates (DACs) with an initial focus on one oncology target.

C4 Therapeutics currently carries a Zacks Rank #2. In the past 60 days, Loss estimates for 2024 have improved from $2.77 per share to $2.55. The company has an ABR of 1.91. Based on these analyst projections, we expect an average price target of $16.82, indicating a 277.13% upside to the current closing price of $5.27
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CCCC News